People with von Willebrand disease (VWD) are at increased risk of bleeding, which may manifest as frequent nosebleeds, easy bruising, prolonged bleeding from minor cuts, excessive bleeding during dental treatment, and heavy menstrual bleeding.1
Prophylaxis with a von Willebrand factor (VWF) concentrate is recommended to prevent bleeding in people with severe von Willebrand disease.2, 3 wilate® prophylaxis is effective in adults, adolescents and children with all von Willebrand disease types, reducing the rate of bleeding compared with on-demand treatment.4
Prophylaxis with VWF concentrates*
* Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Can effectively
prevent bleeding2
May reduce the burden of von Willebrand disease and improve quality of life2
Is recommended in patients with severe von Willebrand disease4
A significant proportion of people with von Willebrand disease may be undertreated2
of patients with severe von Willebrand disease receive prophylaxis with VWF concentrates5
Efficacy of wilate® prophylaxis has been demonstrated in
Prospective clinical trials in adults4 and children4,6
Data from 4 prospective, multicentre Phase II/III trials
Data from 4 prospective, multicentre Phase II/III trials
of patients had
type 3 VWD
median (range 3-46 months) duration of prophylaxis
Data from 4 prospective, multicentre Phase II/III trials
Bleeding frequency significantly reduced after the start of wilate® prophylaxis
Information about on-demand treatment with wilate®
Surgical prophylaxis with wilate®
Use of wilate® in people with von Willebrand disease
The information on this website is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Octapharma representative for the latest information specific to your country.
Please contact your local Octapharma representative for local prescribing information via our contact form.
IMPORTANT
The information on this website is based on the European Summary of Product Characteristics (EU SmPC). US HCPs and other country-specific websites: Below is a list of countries that host a local wilate® website based on local approved information and in local language. Click on the country link to be redirected to the local wilate® website.
The website is provided by Octapharma AG, Seidenstrasse 2, 8853 Lachen, Switzerland
www.octapharma.com
© 2024 Octapharma AG